Enrollment and Drug Access

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »

Getting your patients started on therapy

PAH Pathways^® offers patients on Ventavis a clear path to getting started on therapy. Working with your office, PAH Pathways and specialty pharmacies make it easier for your patients to get their medicine when they need it. Here's how it all comes together:

Ventavis Enrollment

1. You prescribe Ventavis by completing enrollment forms: The process starts when your office faxes your patient's Ventavis enrollment forms to PAH Pathways at 1-866-279-0669.

2. PAH Pathways contacts your patient: Once we receive your patient's Ventavis enrollment forms, PAH Pathways will:

Contact your patient to discuss starting Ventavis and answer enrollment questions they may have
Forward your patient's information to an in-network specialty pharmacy, who will discuss insurance coverage with your patient, and deliver Ventavis directly to your patient's home
Mail your patient a Ventavis Welcome Folder

3. Specialty pharmacy coordinates your patient's insurance coverage: Ventavis is not available in retail pharmacies; rather, it is carried by a limited network of specialty pharmacies. Once your patient's information has been sent to a specialty pharmacy, the pharmacy will:

Obtain insurance approval and determine your patient's benefit status for Ventavis and the I-neb AAD System
Notify your patient of their out-of-pocket expenses
Provide information on financial assistance programs, if needed. Click here to learn more about available financial assistance.

4. Your patient receives Ventavis and device training: Your patient's specialty pharmacy ships Ventavis and the I-neb AAD System directly to your patient's home or to your office. The specialty pharmacy also schedules a training session for your patient so that they can understand how and when to take Ventavis. By using long and slow breaths, many patients have decreased their treatment times. A specialty pharmacy nurse educator conducts a patient training session, which can take place at your patient's home or in a location that's convenient.

Know that if at any time your patient has a problem with their I-neb AAD System (for example, the I-neb AAD System is not working), they can call their specialty pharmacy's 24-hour emergency service number to arrange delivery of a replacement device. A specialty pharmacy nurse educator conducts a patient training session.

5. Your patient receives ongoing support: Know that at any time after your patient has started on therapy, they can contact PAH Pathways with questions or concerns about the delivery of medicine, insurance coverage, or financial assistance programs.

You can also call PAH Pathways, Monday through Friday, 9 AM-8 PM (ET)/6 AM-5 PM (PT), with questions about any of these steps: 1-866-ACTELION (228-3546).

Do your patients need insurance coverage information and financial assistance programs?

Download Ventavis Patient Enrollment forms

Respironics and I-neb are trademarks of or belonging to Koninklijke Philips Electronics N.V.

Ventavis Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Ventavis Important Safety Information:

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information for Ventavis.

Tracleer Indication:

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital systemic-to-pulmonary shunts (18%).

Considerations for use
Patients with WHO class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of liver injury in WHO class II patients, which may preclude future use as their disease progresses.

Please see full Prescribing Information, including BOXED WARNING about liver injury and pregnancy.